Enovis Co. (NYSE:ENOV) Shares Bought by Tributary Capital Management LLC

Tributary Capital Management LLC raised its stake in Enovis Co. (NYSE:ENOV) by 33.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 566,089 shares of the company’s stock after buying an additional 143,258 shares during the quarter. Enovis comprises about 1.9% of Tributary Capital Management LLC’s portfolio, making the stock its 15th biggest holding. Tributary Capital Management LLC owned about 1.01% of Enovis worth $24,840,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. UMB Bank n.a. increased its stake in Enovis by 128.2% during the fourth quarter. UMB Bank n.a. now owns 778 shares of the company’s stock worth $34,000 after purchasing an additional 437 shares during the period. Pinnacle Bancorp Inc. increased its stake in Enovis by 54.5% during the fourth quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock worth $37,000 after purchasing an additional 300 shares during the period. DekaBank Deutsche Girozentrale purchased a new stake in Enovis during the third quarter worth about $55,000. Benjamin F. Edwards & Company Inc. increased its stake in Enovis by 28.1% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,691 shares of the company’s stock worth $76,000 after purchasing an additional 371 shares during the period. Finally, FMR LLC increased its stake in Enovis by 20.5% during the third quarter. FMR LLC now owns 2,840 shares of the company’s stock worth $122,000 after purchasing an additional 484 shares during the period. Institutional investors and hedge funds own 98.45% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on ENOV. JMP Securities began coverage on shares of Enovis in a research note on Thursday, October 3rd. They set an “outperform” rating and a $62.00 price target on the stock. Evercore ISI cut their target price on shares of Enovis from $62.00 to $58.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 1st. Finally, Needham & Company LLC restated a “buy” rating and set a $65.00 target price on shares of Enovis in a research note on Thursday, November 7th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $65.86.

Enovis Price Performance

Shares of Enovis stock opened at $47.78 on Friday. Enovis Co. has a 52 week low of $38.27 and a 52 week high of $65.03. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. The firm’s 50 day moving average is $45.93 and its two-hundred day moving average is $44.45.

Enovis (NYSE:ENOV) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.73 EPS for the quarter, beating the consensus estimate of $0.62 by $0.11. The company had revenue of $505.22 million for the quarter, compared to analyst estimates of $504.44 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The firm’s revenue was up 21.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.56 earnings per share. On average, analysts predict that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.